Literature DB >> 33845847

Overexpressing PTTG family genes predict poor prognosis in kidney renal clear cell carcinoma.

Yonghui Gui1, Xueni Liu1, Chao Wang1, Peng Yang2.   

Abstract

BACKGROUND: Pituitary tumor transforming genes (PTTG1, PTTG2, and PTTG3P) play key roles in the pathogenesis and development of human cancers. The studies show that overexpression of the PTTG genes is associated with tumor progression and migration. However, the function of the PTTG genes in the prognostic value of kidney renal clear cell carcinoma is rarely known by people.
METHODS: The expression of PTTG family genes was analyzed by the ONCOMINE, Human Protein Atlas, GEPIA2, and UALCAN database. The relationship between PTTG family genes expression level and clinical indicators including prognostic data in kidney renal clear cell carcinoma was analyzed by GEPIA2, TCGA portal, and UALCAN. cBioPortal database was used to analyze the genetic mutations of differentially expressed PTTG family members. Similar genes of the PTTG family (90 in total) obtained from GEPIA2 and Metascape were used for GO enrichment to explore the interaction among similar genes. The online tools of Metascape and STRING were used for functional and pathway enrichment analysis.
RESULTS: PTTG1, 2, and 3P mRNA and protein expression upregulated in kidney renal clear cell carcinoma kidney renal clear cell carcinoma patients compared with normal tissues. And higher expression level of PTTG family genes was associated with shorter overall survival (OS) and disease-free survival (DFS). Furthermore, overexpression of the PTTG family genes had been found correlated with individual cancer stages and pathological tumor grades. In addition, 18% of mutations in the PTTG family genes were associated with short-term survival in kidney renal clear cell carcinoma patients.
CONCLUSIONS: A single PTTG gene or PTTG family genes as a whole may be a potential prognostic biomarker for kidney renal clear cell carcinoma.

Entities:  

Keywords:  Biomarker; KIRC; PTTG; Prognostic

Year:  2021        PMID: 33845847     DOI: 10.1186/s12957-021-02225-2

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  12 in total

Review 1.  PTEN in kidney cancer: A review and meta-analysis.

Authors:  Wan-Cai Que; Hong-Qiang Qiu; Yu Cheng; Mao-Bai Liu; Chao-Yang Wu
Journal:  Clin Chim Acta       Date:  2018-02-02       Impact factor: 3.786

2.  Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research.

Authors:  Anna Asplund; Per-Henrik D Edqvist; Jochen M Schwenk; Fredrik Pontén
Journal:  Proteomics       Date:  2012-07       Impact factor: 3.984

3.  MicroRNA-329-mediated PTTG1 downregulation inactivates the MAPK signaling pathway to suppress cell proliferation and tumor growth in cholangiocarcinoma.

Authors:  Zhi-Gao Hu; Chao-Wen Zheng; Hui-Zhao Su; Yong-Lian Zeng; Cheng-Jie Lin; Zhen-Ya Guo; Fu-Di Zhong; Guan-Dou Yuan; Song-Qing He
Journal:  J Cell Biochem       Date:  2018-12-23       Impact factor: 4.429

4.  Correlation of apparent diffusion coefficient value with prognostic parameters of lung cancer.

Authors:  Ahmed Abdel Khalek Abdel Razek; Amal Fathy; Taha Abdel Gawad
Journal:  J Comput Assist Tomogr       Date:  2011 Mar-Apr       Impact factor: 1.826

5.  Upregulation of PTTG1 is associated with poor prognosis in prostate cancer.

Authors:  Christoph Fraune; Serhiy Yehorov; Andreas M Luebke; Stefan Steurer; Claudia Hube-Magg; Franziska Büscheck; Doris Höflmayer; Maria Christina Tsourlakis; Till S Clauditz; Ronald Simon; Guido Sauter; Sören Weidemann; David Dum; Simon Kind; Sarah Minner; Thorsten Schlomm; Hartwig Huland; Hans Heinzer; Markus Graefen; Eike Burandt
Journal:  Pathol Int       Date:  2020-04-20       Impact factor: 2.534

6.  Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma.

Authors:  Minerva Angélica Romero Arenas; Timothy G Whitsett; Anna Aronova; Samuel A Henderson; Janine LoBello; Mouhammed Amir Habra; Elizabeth G Grubbs; Jeffrey E Lee; Kanishka Sircar; Rasa Zarnegar; Theresa Scognamiglio; Thomas J Fahey; Nancy D Perrier; Michael J Demeure
Journal:  Ann Surg Oncol       Date:  2017-12-07       Impact factor: 5.344

7.  PTTG3P promotes gastric tumour cell proliferation and invasion and is an indicator of poor prognosis.

Authors:  Weiwei Weng; Shujuan Ni; Yiqin Wang; Midie Xu; Qiongyan Zhang; Yusi Yang; Yong Wu; Qinghua Xu; Peng Qi; Cong Tan; Dan Huang; Ping Wei; Zhaohui Huang; Yuqing Ma; Wei Zhang; Weiqi Sheng; Xiang Du
Journal:  J Cell Mol Med       Date:  2017-06-19       Impact factor: 5.310

8.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.

Authors:  Darshan S Chandrashekar; Bhuwan Bashel; Sai Akshaya Hodigere Balasubramanya; Chad J Creighton; Israel Ponce-Rodriguez; Balabhadrapatruni V S K Chakravarthi; Sooryanarayana Varambally
Journal:  Neoplasia       Date:  2017-07-18       Impact factor: 5.715

9.  Distinct expression pattern and prognostic values of pituitary tumor transforming gene family genes in non-small cell lung cancer.

Authors:  Shaolong Yang; Xiaodi Wang; Jingxing Liu; Bisha Ding; Kairi Shi; Jing Chen; Weiyang Lou
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

10.  PTTG1 is involved in TNF-α-related hepatocellular carcinoma via the induction of c-myc.

Authors:  Xianyi Lin; Yidong Yang; Yunwei Guo; Huiling Liu; Jie Jiang; Fengping Zheng; Bin Wu
Journal:  Cancer Med       Date:  2019-08-06       Impact factor: 4.452

View more
  2 in total

1.  Biological Function and Clinical Value of VPS13A in Pan-Cancer Based on Bioinformatics Analysis.

Authors:  Xue Qin Zhang; Li Li
Journal:  Int J Gen Med       Date:  2021-10-16

2.  Construction of an individualized clinical prognostic index based on ubiquitination-associated lncRNA in clear cell renal cell carcinoma patients.

Authors:  Kun Liu; Xuzhong Liu; Qing Sun; Zhiwang Tang; Gongcheng Wang; Zongyuan Xu
Journal:  World J Surg Oncol       Date:  2022-05-10       Impact factor: 3.253

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.